4-(3-Chloro-4-methoxy-benzylamino)-2-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-pyrimidine-5-carbaldehyde | 330785-87-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(3-Chloro-4-methoxy-benzylamino)-2-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-pyrimidine-5-carbaldehyde
• 英文别名: (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine；4-[(3-chloro-4-methoxyphenyl)methylamino]-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]pyrimidine-5-carbaldehyde
• CAS: 330785-87-0
• 化学式: C₁₈H₂₁ClN₄O₃
• 分子量: 376.843
• InChiKey: BGWWPPIKYCSEDY-AWEZNQCLSA-N

物化性质

• 沸点：
  613.4±65.0 °C(Predicted)
• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  87.6
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-(3-Chloro-4-methoxy-benzylamino)-2-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-pyrimidine-5-carbaldehyde 在 正丁基锂 、 二环己胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 8-(3-Chloro-4-methoxy-benzyl)-2-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-5-(2-morpholin-4-yl-ethyl)-8H-pyrido[2,3-d]pyrimidin-7-one
  参考文献：
  名称：

  8-(3-Chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors

  摘要：

  A novel series of highly selective phosphodiesterase 5 (PDE5) inhibitors was found. 8H-Pyrido[2,3-d]pyrimidin-7-one derivatives bearing an (S)-2-(hydroxymethyl)pyrrolidin-1-yl group at the 2-position and a 3-chloro-4-methoxybenzyl group at the 8-position exhibited potent PDE5 inhibitory activities and high PDE5 selectivity over PDE6. Among the synthesized compounds, the 5-methyl analogue (5b) showed the most potent relaxant effect on isolated rabbit corpus cavernosum with an EC30 value of 0.85 nM. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.02.041
• 作为产物：
  描述：

  3-氯-4-甲氧基苄胺 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 氯仿 为溶剂， 生成 4-(3-Chloro-4-methoxy-benzylamino)-2-((S)-2-hydroxymethyl-pyrrolidin-1-yl)-pyrimidine-5-carbaldehyde
  参考文献：
  名称：

  8-(3-Chloro-4-methoxybenzyl)-8H-pyrido[2,3-d]pyrimidin-7-one derivatives as potent and selective phosphodiesterase 5 inhibitors

  摘要：

  A novel series of highly selective phosphodiesterase 5 (PDE5) inhibitors was found. 8H-Pyrido[2,3-d]pyrimidin-7-one derivatives bearing an (S)-2-(hydroxymethyl)pyrrolidin-1-yl group at the 2-position and a 3-chloro-4-methoxybenzyl group at the 8-position exhibited potent PDE5 inhibitory activities and high PDE5 selectivity over PDE6. Among the synthesized compounds, the 5-methyl analogue (5b) showed the most potent relaxant effect on isolated rabbit corpus cavernosum with an EC30 value of 0.85 nM. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.02.041

文献信息

• Cyclic compounds
  申请人：——

  公开号：US20040142930A1

  公开（公告）日：2004-07-22

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, 1 wherein X is ═CH— or ═N—, Y is —NH—, —NR 4 —, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R 1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R 2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R 3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R 3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  化合物的公式（I）或其药理学上可接受的盐，其中X为═CH—或═N—，Y为—NH—，—NR4—，—S—，—O—，—CH═N—，—N═CH—，—N═N—，—CH═CH—等，R1为较低的烷氧基，氨基，含N原子的杂环环，或者由含N原子的杂环环取代的羟基（每个都可以取代），R2为较低的烷基氨基基，可以由芳基取代，较低的烷氧基，可以由芳基取代，由含N原子的芳基取代的较低的烷氧基，R3为芳基，含N原子的杂环环，较低的烷基，较低的烷氧基，环状较低的烷氧基，由含N原子的杂环环取代的羟基，或者氨基（每个都可以取代），R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• Aromatic nitrogen-containing 6-membered cyclic compounds
  申请人：——

  公开号：US20030032647A1

  公开（公告）日：2003-02-13

  An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): 1 wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R 1 is a substituted or unsubstituted lower alkyl group, —NH—Q—R 3 (R 3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or —NH—R 4 (R 4 is a substituted or unsubstituted cycloalkyl group); R 2 is a substituted or unsubstituted aryl group; one of Y and Z is ═CH—, and the other is ═N—, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.

  一种芳香性氮含量的6元环化合物，化学式为(I)：其中环A是取代或未取代的含氮杂环基团；R1是取代或未取代的较低烷基基团，-NH-Q-R3（R3是取代或未取代的含氮杂环基团，Q是较低烷基烃基团或单键），或-NH-R4（R4是取代或未取代的环烷基基团）；R2是取代或未取代的芳基团；Y和Z中的一个是═CH—，另一个是═N—，或其药学上可接受的盐，这些化合物表现出优异的选择性PDE V抑制活性，因此在预防或治疗阴茎勃起功能障碍等方面具有用处。
• Aromatic nitrogen-containig 6-membered cyclic compounds
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US20030229095A1

  公开（公告）日：2003-12-11

  An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): 1 wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R 1 is a substituted or unsubstituted lower alkyl group, —NH—Q—R 3 (R 3 is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or —NH—R 4 (R 4 is a substituted or unsubstituted cycloalkyl group); R 2 is a substituted or unsubstituted aryl group; one of Y and Z is ═CH—, and the other is ═N—, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.

  一种含有芳香性质的氮，6元环化合物，化学式为(I):1，其中环A为取代或未取代的含氮杂环基团; R1为取代或未取代的低级烷基基团，-NH-Q-R3(R3为取代或未取代的含氮杂环基团，Q为低级亚烷基基团或单键)，或-NH-R4(R4为取代或未取代的环烷基基团)；R2为取代或未取代的芳基基团；Y和Z中的一个为═CH—，另一个为═N—或其药学上可接受的盐。这些化合物表现出优异的选择性PDE V抑制活性，因此在预防或治疗阴茎勃起功能障碍等方面具有用途。
• Pyridopyrimidine or naphthyridine derivative
  申请人：Yamada Koichiro

  公开号：US20050101615A1

  公开（公告）日：2005-05-12

  A pyridopyrimidine or a naphthyridine derivative of the formula (I): wherein R 1 is an optionally substituted nitrogen-containing heterocyclic group, etc.; R 2 is H or a lower alkyl group; R 3 is H or an optionally substituted lower alkyl group, etc.; R 4 is H, a lower alkyl group, COOH, etc.; R 5 is a lower alkyl group which may optionally be substituted by an optionally substituted aryl etc.; one of X and Y is CH and the other is nitrogen, or both of X and Y are nitrogen; or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent PDE V inhibitory activities, and being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.

  公式（I）中的吡啶并嘧啶或萘啶衍生物，其中R1是可选取代的含氮杂环基团等；R2是氢或较低的烷基基团；R3是氢或可选取代的较低烷基基团等；R4是氢、较低的烷基基团、COOH等；R5是较低的烷基基团，其可以可选取代芳基等；X和Y中的一个是CH，另一个是氮，或者X和Y都是氮；或其药学上可接受的盐，这些化合物表现出优异的PDE V抑制活性，并且在预防或治疗阴茎勃起功能障碍等方面非常有用。
• Pyrazine derivatives
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US07273868B2

  公开（公告）日：2007-09-25

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  公式（I）的环状化合物或其药学上可接受的盐，其中X为═CH—或═N—，Y为—NH—、—NR4—、—S—、—O—、—CH═N—、—N═CH—、—N═N—、—CH═CH—等，R1为较低的烷氧基、氨基、含N原子的杂环环或由含N原子的杂环环取代的羟基（每个都可以选择性地取代），R2为较低的烷基氨基，可以选择性地被芳基取代，也可以选择性地被芳基取代的较低的烷氧基，被含N原子的芳香杂环环取代的较低的烷氧基，R3为芳基、含N原子的杂环环、较低的烷基、较低的烷氧基、环状较低的烷氧基、由含N原子的杂环环取代的羟基或氨基（每个都可以选择性地取代），R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有出色的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。